Company intelligence / Profile preview

Direct Protection

Austin, Texas, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Commercial

Overview

Direct Biologics' lead product, ExoFlo™, demonstrated significant survival benefit in a phase II randomized controlled trial for hospitalized patients with moderate-to-severe acute respiratory distress syndrome due to COVID. The company also received FDA clearance to initiate a phase Ib/IIa clinical trial of ExoFlo™ for medically refractory perianal fistulizing Crohn's Disease. Expanded access data show compelling results across more than one hundred subjects treated under emergency use protocols.

Therapeutic areas: PulmonologyGastroenterology
Modalities: Extracellular vesicle therapyCell therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Direct Protection.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Direct Protection.

Explore the full profile